Global Hypoparathyroidism Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Hypoparathyroidism treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Alize Pharma 3, Ascendis Pharma A/S, Chugai Pharmaceutical Co Ltd, Eli Lilly and Co, Entera Bio Ltd and others.
A Significant contribution to the Hypoparathyroidism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Hypoparathyroidism pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Hypoparathyroidism condition and increased access to investments is encouraging growth of Hypoparathyroidism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Hypoparathyroidism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Hypoparathyroidism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Hypoparathyroidism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Hypoparathyroidism . Further, orphan drug status, fast track designation, grants awarded and other special status for Hypoparathyroidism pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Hypoparathyroidism pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Hypoparathyroidism Pipeline candidates-
A Significant contribution to the Hypoparathyroidism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Hypoparathyroidism pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Hypoparathyroidism condition and increased access to investments is encouraging growth of Hypoparathyroidism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Hypoparathyroidism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Hypoparathyroidism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Hypoparathyroidism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Hypoparathyroidism . Further, orphan drug status, fast track designation, grants awarded and other special status for Hypoparathyroidism pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Hypoparathyroidism pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Hypoparathyroidism Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Hypoparathyroidism drugs
- Late phase: Phase 3 and in-approval Hypoparathyroidism drugs
- Company overview
- Snapshot
- Hypoparathyroidism therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Hypoparathyroidism - Disease Overview
2.2 Hypoparathyroidism - Pipeline Snapshot
2.3 Hypoparathyroidism - Pipeline Drugs by Phase
2.4 Hypoparathyroidism - Pipeline Drugs by Company
2.5 Hypoparathyroidism - Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Alize Pharma 3 Hypoparathyroidism Drug Pipeline, H2- 2019
3.2 Ascendis Pharma A/S Hypoparathyroidism Drug Pipeline, H2- 2019
3.3 Chugai Pharmaceutical Co Ltd Hypoparathyroidism Drug Pipeline, H2- 2019
3.4 Eli Lilly and Co Hypoparathyroidism Drug Pipeline, H2- 2019
3.5 Entera Bio Ltd Hypoparathyroidism Drug Pipeline, H2- 2019
3.6 Extend Biosciences Inc Hypoparathyroidism Drug Pipeline, H2- 2019
3.7 GC Pharma Hypoparathyroidism Drug Pipeline, H2- 2019
3.8 Takeda Pharmaceutical Co Ltd Hypoparathyroidism Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Hypoparathyroidism - Phase 1 Drug Details
4.2 Hypoparathyroidism - Phase 1 Drug Overview
4.3 Hypoparathyroidism - Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Hypoparathyroidism - Phase 2 Drug Details
5.2 Hypoparathyroidism - Phase 2 Drug Overview
5.3 Hypoparathyroidism - Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Hypoparathyroidism - Phase 3 Drug Details
6.2 Hypoparathyroidism - Phase 3 Drug Overview
6.3 Hypoparathyroidism - Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Hypoparathyroidism - Pre-clinical Phase Drug Details
7.2 Hypoparathyroidism - Pre-clinical Phase Drug Overview
7.3 Hypoparathyroidism - Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Hypoparathyroidism - Disease Overview
2.2 Hypoparathyroidism - Pipeline Snapshot
2.3 Hypoparathyroidism - Pipeline Drugs by Phase
2.4 Hypoparathyroidism - Pipeline Drugs by Company
2.5 Hypoparathyroidism - Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Alize Pharma 3 Hypoparathyroidism Drug Pipeline, H2- 2019
3.2 Ascendis Pharma A/S Hypoparathyroidism Drug Pipeline, H2- 2019
3.3 Chugai Pharmaceutical Co Ltd Hypoparathyroidism Drug Pipeline, H2- 2019
3.4 Eli Lilly and Co Hypoparathyroidism Drug Pipeline, H2- 2019
3.5 Entera Bio Ltd Hypoparathyroidism Drug Pipeline, H2- 2019
3.6 Extend Biosciences Inc Hypoparathyroidism Drug Pipeline, H2- 2019
3.7 GC Pharma Hypoparathyroidism Drug Pipeline, H2- 2019
3.8 Takeda Pharmaceutical Co Ltd Hypoparathyroidism Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Hypoparathyroidism - Phase 1 Drug Details
4.2 Hypoparathyroidism - Phase 1 Drug Overview
4.3 Hypoparathyroidism - Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Hypoparathyroidism - Phase 2 Drug Details
5.2 Hypoparathyroidism - Phase 2 Drug Overview
5.3 Hypoparathyroidism - Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Hypoparathyroidism - Phase 3 Drug Details
6.2 Hypoparathyroidism - Phase 3 Drug Overview
6.3 Hypoparathyroidism - Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Hypoparathyroidism - Pre-clinical Phase Drug Details
7.2 Hypoparathyroidism - Pre-clinical Phase Drug Overview
7.3 Hypoparathyroidism - Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
